Cargando…

Placental Mesenchymal Dysplasia and Beckwith–Wiedemann Syndrome

SIMPLE SUMMARY: Placental mesenchymal dysplasia (PMD) is a morphological abnormality resembling partial hydatidiform moles without abnormal trophoblastic proliferation. In PMD, approximately 20% of fetuses have Beckwith–Wiedemann syndrome (BWS), and approximately 20% of BWS fetuses are associated wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Soejima, Hidenobu, Hara, Satoshi, Ohba, Takashi, Higashimoto, Ken
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688415/
https://www.ncbi.nlm.nih.gov/pubmed/36428656
http://dx.doi.org/10.3390/cancers14225563
_version_ 1784836263059128320
author Soejima, Hidenobu
Hara, Satoshi
Ohba, Takashi
Higashimoto, Ken
author_facet Soejima, Hidenobu
Hara, Satoshi
Ohba, Takashi
Higashimoto, Ken
author_sort Soejima, Hidenobu
collection PubMed
description SIMPLE SUMMARY: Placental mesenchymal dysplasia (PMD) is a morphological abnormality resembling partial hydatidiform moles without abnormal trophoblastic proliferation. In PMD, approximately 20% of fetuses have Beckwith–Wiedemann syndrome (BWS), and approximately 20% of BWS fetuses are associated with PMD. In addition, PMD is a cardinal feature of BWS, and paternal uniparental diploidy/biparental diploidy mosaicism (also called androgenetic/biparental mosaicism) has been found in both BWS and PMD. This suggests that there is a molecular link between BWS and PMD. In this review, we focus on the etiologies of BWS and PMD and describe the molecular link between them. Both conditions are imprinting disorders that, depending on the case, may share or differ in molecular characteristics. These observations raise questions concerning the timing of the occurrence of the molecularly abnormal cells during the postfertilization period and the effects of these abnormalities on cell fates after implantation. ABSTRACT: Placental mesenchymal dysplasia (PMD) is characterized by placentomegaly, aneurysmally dilated chorionic plate vessels, thrombosis of the dilated vessels, and large grapelike vesicles, and is often mistaken for partial or complete hydatidiform mole with a coexisting normal fetus. Androgenetic/biparental mosaicism (ABM) has been found in many PMD cases. Beckwith–Wiedemann syndrome (BWS) is an imprinting disorder with complex and diverse phenotypes and an increased risk of developing embryonal tumors. There are five major causative alterations: loss of methylation of imprinting control region 2 (KCNQ1OT1:TSS-DMR) (ICR2-LOM), gain of methylation at ICR1 (H19/IGF2:IG-DMR) (ICR1-GOM), paternal uniparental disomy of 11 (pUPD11), loss-of-function variants of the CDKN1C gene, and paternal duplication of 11p15. Additional minor alterations include genetic variants within ICR1, paternal uniparental diploidy/biparental diploidy mosaicism (PUDM, also called ABM), and genetic variants of KCNQ1. ABM (PUDM) is found in both conditions, and approximately 20% of fetuses from PMD cases are BWS and vice versa, suggesting a molecular link. PMD and BWS share some molecular characteristics in some cases, but not in others. These findings raise questions concerning the timing of the occurrence of the molecularly abnormal cells during the postfertilization period and the effects of these abnormalities on cell fates after implantation.
format Online
Article
Text
id pubmed-9688415
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96884152022-11-25 Placental Mesenchymal Dysplasia and Beckwith–Wiedemann Syndrome Soejima, Hidenobu Hara, Satoshi Ohba, Takashi Higashimoto, Ken Cancers (Basel) Review SIMPLE SUMMARY: Placental mesenchymal dysplasia (PMD) is a morphological abnormality resembling partial hydatidiform moles without abnormal trophoblastic proliferation. In PMD, approximately 20% of fetuses have Beckwith–Wiedemann syndrome (BWS), and approximately 20% of BWS fetuses are associated with PMD. In addition, PMD is a cardinal feature of BWS, and paternal uniparental diploidy/biparental diploidy mosaicism (also called androgenetic/biparental mosaicism) has been found in both BWS and PMD. This suggests that there is a molecular link between BWS and PMD. In this review, we focus on the etiologies of BWS and PMD and describe the molecular link between them. Both conditions are imprinting disorders that, depending on the case, may share or differ in molecular characteristics. These observations raise questions concerning the timing of the occurrence of the molecularly abnormal cells during the postfertilization period and the effects of these abnormalities on cell fates after implantation. ABSTRACT: Placental mesenchymal dysplasia (PMD) is characterized by placentomegaly, aneurysmally dilated chorionic plate vessels, thrombosis of the dilated vessels, and large grapelike vesicles, and is often mistaken for partial or complete hydatidiform mole with a coexisting normal fetus. Androgenetic/biparental mosaicism (ABM) has been found in many PMD cases. Beckwith–Wiedemann syndrome (BWS) is an imprinting disorder with complex and diverse phenotypes and an increased risk of developing embryonal tumors. There are five major causative alterations: loss of methylation of imprinting control region 2 (KCNQ1OT1:TSS-DMR) (ICR2-LOM), gain of methylation at ICR1 (H19/IGF2:IG-DMR) (ICR1-GOM), paternal uniparental disomy of 11 (pUPD11), loss-of-function variants of the CDKN1C gene, and paternal duplication of 11p15. Additional minor alterations include genetic variants within ICR1, paternal uniparental diploidy/biparental diploidy mosaicism (PUDM, also called ABM), and genetic variants of KCNQ1. ABM (PUDM) is found in both conditions, and approximately 20% of fetuses from PMD cases are BWS and vice versa, suggesting a molecular link. PMD and BWS share some molecular characteristics in some cases, but not in others. These findings raise questions concerning the timing of the occurrence of the molecularly abnormal cells during the postfertilization period and the effects of these abnormalities on cell fates after implantation. MDPI 2022-11-12 /pmc/articles/PMC9688415/ /pubmed/36428656 http://dx.doi.org/10.3390/cancers14225563 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Soejima, Hidenobu
Hara, Satoshi
Ohba, Takashi
Higashimoto, Ken
Placental Mesenchymal Dysplasia and Beckwith–Wiedemann Syndrome
title Placental Mesenchymal Dysplasia and Beckwith–Wiedemann Syndrome
title_full Placental Mesenchymal Dysplasia and Beckwith–Wiedemann Syndrome
title_fullStr Placental Mesenchymal Dysplasia and Beckwith–Wiedemann Syndrome
title_full_unstemmed Placental Mesenchymal Dysplasia and Beckwith–Wiedemann Syndrome
title_short Placental Mesenchymal Dysplasia and Beckwith–Wiedemann Syndrome
title_sort placental mesenchymal dysplasia and beckwith–wiedemann syndrome
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688415/
https://www.ncbi.nlm.nih.gov/pubmed/36428656
http://dx.doi.org/10.3390/cancers14225563
work_keys_str_mv AT soejimahidenobu placentalmesenchymaldysplasiaandbeckwithwiedemannsyndrome
AT harasatoshi placentalmesenchymaldysplasiaandbeckwithwiedemannsyndrome
AT ohbatakashi placentalmesenchymaldysplasiaandbeckwithwiedemannsyndrome
AT higashimotoken placentalmesenchymaldysplasiaandbeckwithwiedemannsyndrome